Cardiovascular disease and adult healing cells: From bench top to bedside

Henry E. Young, Jason Ionnis Limnios, Frank Lachner, George McCommon, Gypsy F. Black, Julie Coleman, Kristina C Hawkins, Shanna Williams, Asa C Black Jr.

Research output: Contribution to journalArticleResearchpeer-review

21 Downloads (Pure)

Abstract

Cardiovascular disease, especially ischemic heart disease resulting from coronary artery disease (CAD), is one of the major causes of death and disability in the United States. Even though the dead myocardial cells can be replaced by scar tissue in the healing process, the resulting myocardium cannot function as well as the preinfarcted myocardium, because scar tissues cannot contract. This “normal” healing process results in decreased cardiac output, which can lead to heart failure. Moreover, the scar tissue has abnormal electrical properties, which can lead to sometimes fatal arrhythmias. Previous studies demonstrated that when Lac-Z-labeled healing cells were infused into two animal models of myocardial infarction, that these cells were found to be located within the myocardium, the cardiac skeleton, and the vasculature undergoing repair. These results suggested that healing cells have the potential to repair damaged hearts. The current series of studies were undertaken to determine whether healing cells customarily reside in normal non-injured hearts of small and large animals, and whether autologous healing cells could be infused safely into a post-myocardial infarction patient. Adult rats were euthanized following the guidelines of Mercer University’s IACUC. Adult pigs were euthanized following the guidelines of Fort Valley State University’s IACUC. The human study was performed under the guidance of the Medical Center of Central Georgia’s IRB. Animal hearts were harvested, fixed, cryosectioned, and stained with three antibodies: carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) for totipotent stem cells, stage-specific embryonic antigen-4 (SSEA-4) for pluripotent stem cells, and smooth muscle alpha-actin (IA4) for smooth muscle in the wall of the accompanying vasculature, thus serving as the positive procedural control. Cells positive for both CEA-CAM-1 and SSEA-4 were found to be located in adult rat and porcine hearts. Infusion of autologous healing cells into a post-myocardial infarcted patient resulted in an increase in their cardiac output after two successive healing cell infusions. Current IRB-approved studies are underway to assess the safety and efficacy of infused healing cells into individuals with cardiovascular disease.
Original languageEnglish
Number of pages8
JournalJournal of Stem Cell Research
Volume1
Issue number3
Publication statusPublished - 24 Nov 2017

Fingerprint

Cardiovascular Diseases
Animal Care Committees
Cicatrix
Myocardium
Research Ethics Committees
Carcinoembryonic Antigen
Cell Adhesion Molecules
Cardiac Output
Smooth Muscle
Totipotent Stem Cells
Swine
Myocardial Infarction
Guidelines
Pluripotent Stem Cells
Skeleton
Myocardial Ischemia
Actins
Cardiac Arrhythmias
Coronary Artery Disease
Cause of Death

Cite this

Young, H. E., Limnios, J. I., Lachner, F., McCommon, G., Black, G. F., Coleman, J., ... Black Jr., A. C. (2017). Cardiovascular disease and adult healing cells: From bench top to bedside. Journal of Stem Cell Research, 1(3).
Young, Henry E. ; Limnios, Jason Ionnis ; Lachner, Frank ; McCommon, George ; Black, Gypsy F. ; Coleman, Julie ; Hawkins, Kristina C ; Williams, Shanna ; Black Jr., Asa C. / Cardiovascular disease and adult healing cells : From bench top to bedside. In: Journal of Stem Cell Research. 2017 ; Vol. 1, No. 3.
@article{57558f8bf101460dab332f50814b440e,
title = "Cardiovascular disease and adult healing cells: From bench top to bedside",
abstract = "Cardiovascular disease, especially ischemic heart disease resulting from coronary artery disease (CAD), is one of the major causes of death and disability in the United States. Even though the dead myocardial cells can be replaced by scar tissue in the healing process, the resulting myocardium cannot function as well as the preinfarcted myocardium, because scar tissues cannot contract. This “normal” healing process results in decreased cardiac output, which can lead to heart failure. Moreover, the scar tissue has abnormal electrical properties, which can lead to sometimes fatal arrhythmias. Previous studies demonstrated that when Lac-Z-labeled healing cells were infused into two animal models of myocardial infarction, that these cells were found to be located within the myocardium, the cardiac skeleton, and the vasculature undergoing repair. These results suggested that healing cells have the potential to repair damaged hearts. The current series of studies were undertaken to determine whether healing cells customarily reside in normal non-injured hearts of small and large animals, and whether autologous healing cells could be infused safely into a post-myocardial infarction patient. Adult rats were euthanized following the guidelines of Mercer University’s IACUC. Adult pigs were euthanized following the guidelines of Fort Valley State University’s IACUC. The human study was performed under the guidance of the Medical Center of Central Georgia’s IRB. Animal hearts were harvested, fixed, cryosectioned, and stained with three antibodies: carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) for totipotent stem cells, stage-specific embryonic antigen-4 (SSEA-4) for pluripotent stem cells, and smooth muscle alpha-actin (IA4) for smooth muscle in the wall of the accompanying vasculature, thus serving as the positive procedural control. Cells positive for both CEA-CAM-1 and SSEA-4 were found to be located in adult rat and porcine hearts. Infusion of autologous healing cells into a post-myocardial infarcted patient resulted in an increase in their cardiac output after two successive healing cell infusions. Current IRB-approved studies are underway to assess the safety and efficacy of infused healing cells into individuals with cardiovascular disease.",
author = "Young, {Henry E.} and Limnios, {Jason Ionnis} and Frank Lachner and George McCommon and Black, {Gypsy F.} and Julie Coleman and Hawkins, {Kristina C} and Shanna Williams and {Black Jr.}, {Asa C}",
year = "2017",
month = "11",
day = "24",
language = "English",
volume = "1",
journal = "Journal of Stem Cell Research",
issn = "2574-271X",
number = "3",

}

Young, HE, Limnios, JI, Lachner, F, McCommon, G, Black, GF, Coleman, J, Hawkins, KC, Williams, S & Black Jr., AC 2017, 'Cardiovascular disease and adult healing cells: From bench top to bedside' Journal of Stem Cell Research, vol. 1, no. 3.

Cardiovascular disease and adult healing cells : From bench top to bedside. / Young, Henry E.; Limnios, Jason Ionnis; Lachner, Frank; McCommon, George; Black, Gypsy F.; Coleman, Julie; Hawkins, Kristina C; Williams, Shanna; Black Jr., Asa C.

In: Journal of Stem Cell Research, Vol. 1, No. 3, 24.11.2017.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Cardiovascular disease and adult healing cells

T2 - From bench top to bedside

AU - Young, Henry E.

AU - Limnios, Jason Ionnis

AU - Lachner, Frank

AU - McCommon, George

AU - Black, Gypsy F.

AU - Coleman, Julie

AU - Hawkins, Kristina C

AU - Williams, Shanna

AU - Black Jr., Asa C

PY - 2017/11/24

Y1 - 2017/11/24

N2 - Cardiovascular disease, especially ischemic heart disease resulting from coronary artery disease (CAD), is one of the major causes of death and disability in the United States. Even though the dead myocardial cells can be replaced by scar tissue in the healing process, the resulting myocardium cannot function as well as the preinfarcted myocardium, because scar tissues cannot contract. This “normal” healing process results in decreased cardiac output, which can lead to heart failure. Moreover, the scar tissue has abnormal electrical properties, which can lead to sometimes fatal arrhythmias. Previous studies demonstrated that when Lac-Z-labeled healing cells were infused into two animal models of myocardial infarction, that these cells were found to be located within the myocardium, the cardiac skeleton, and the vasculature undergoing repair. These results suggested that healing cells have the potential to repair damaged hearts. The current series of studies were undertaken to determine whether healing cells customarily reside in normal non-injured hearts of small and large animals, and whether autologous healing cells could be infused safely into a post-myocardial infarction patient. Adult rats were euthanized following the guidelines of Mercer University’s IACUC. Adult pigs were euthanized following the guidelines of Fort Valley State University’s IACUC. The human study was performed under the guidance of the Medical Center of Central Georgia’s IRB. Animal hearts were harvested, fixed, cryosectioned, and stained with three antibodies: carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) for totipotent stem cells, stage-specific embryonic antigen-4 (SSEA-4) for pluripotent stem cells, and smooth muscle alpha-actin (IA4) for smooth muscle in the wall of the accompanying vasculature, thus serving as the positive procedural control. Cells positive for both CEA-CAM-1 and SSEA-4 were found to be located in adult rat and porcine hearts. Infusion of autologous healing cells into a post-myocardial infarcted patient resulted in an increase in their cardiac output after two successive healing cell infusions. Current IRB-approved studies are underway to assess the safety and efficacy of infused healing cells into individuals with cardiovascular disease.

AB - Cardiovascular disease, especially ischemic heart disease resulting from coronary artery disease (CAD), is one of the major causes of death and disability in the United States. Even though the dead myocardial cells can be replaced by scar tissue in the healing process, the resulting myocardium cannot function as well as the preinfarcted myocardium, because scar tissues cannot contract. This “normal” healing process results in decreased cardiac output, which can lead to heart failure. Moreover, the scar tissue has abnormal electrical properties, which can lead to sometimes fatal arrhythmias. Previous studies demonstrated that when Lac-Z-labeled healing cells were infused into two animal models of myocardial infarction, that these cells were found to be located within the myocardium, the cardiac skeleton, and the vasculature undergoing repair. These results suggested that healing cells have the potential to repair damaged hearts. The current series of studies were undertaken to determine whether healing cells customarily reside in normal non-injured hearts of small and large animals, and whether autologous healing cells could be infused safely into a post-myocardial infarction patient. Adult rats were euthanized following the guidelines of Mercer University’s IACUC. Adult pigs were euthanized following the guidelines of Fort Valley State University’s IACUC. The human study was performed under the guidance of the Medical Center of Central Georgia’s IRB. Animal hearts were harvested, fixed, cryosectioned, and stained with three antibodies: carcinoembryonic antigen-cell adhesion molecule-1 (CEA-CAM-1) for totipotent stem cells, stage-specific embryonic antigen-4 (SSEA-4) for pluripotent stem cells, and smooth muscle alpha-actin (IA4) for smooth muscle in the wall of the accompanying vasculature, thus serving as the positive procedural control. Cells positive for both CEA-CAM-1 and SSEA-4 were found to be located in adult rat and porcine hearts. Infusion of autologous healing cells into a post-myocardial infarcted patient resulted in an increase in their cardiac output after two successive healing cell infusions. Current IRB-approved studies are underway to assess the safety and efficacy of infused healing cells into individuals with cardiovascular disease.

M3 - Article

VL - 1

JO - Journal of Stem Cell Research

JF - Journal of Stem Cell Research

SN - 2574-271X

IS - 3

ER -

Young HE, Limnios JI, Lachner F, McCommon G, Black GF, Coleman J et al. Cardiovascular disease and adult healing cells: From bench top to bedside. Journal of Stem Cell Research. 2017 Nov 24;1(3).